Mobilization of CD34+ cells by glycosylated and nonglycosylated G‐CSF in healthy volunteers — a comparative study

Publisher Website
Google Scholar
Abstract
In vitro studies indicate that lenograstim (glycosylated G–CSF) is more potent than filgrastim (nonglycosylated G–CSF) on a weight for weight basis. However, such a difference has not yet been shown in vivo. The primary objective of this trial was to compare the efficacy of equivalent doses (μg) of lenograstim and filgrastim in mobilizing CD34+ cells. Thirty‐two healthy male volunteers, median age 27 yr (19–44 yr), were randomized to receive either lenograstim 10 μg/kg followed by filgrastim 10 μg/kg or vice versa with a washout period of a minimum 4 wk. Both drugs were administered as s.c. injections once daily for 5 d (d 1–5). CD34+ cells were mobilized with a similar kinetics, peaking at median d 6 (5–6) for both drugs. A significant difference in favour of lenograstim was shown for peak number of CD34+ cells/μl blood (104±38 vs. 82±35, mean±l SD, pt‐test, n=30) and number of CFU‐GM/μl blood at d 6 (14.6±8.4 vs. 10.2±4.6, pin vivo potency between the two G–CSFs.

This publication has 23 references indexed in Scilit: